CIK 0000875320
- Large accelerated filer
VERTEX PHARMACEUTICALS INC / MA
Sign in to watch- Ticker
- VRTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- MA
- Entity type
- Operating
- EIN
- 043039129
- Phone
- +1 617-341-6393
- Business address
- 50 NORTHERN AVENUE, BOSTON, MA, 02210
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $15,378,206
- in 4 filings, $15.4M under 10b5-1 plans
Net −$15,378,206. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-10-03 | Bozic Carmen EVP and CMO | Sale 10b5-1 | −5,651 | $345.28 | $2.0M | 46,254 |
| 2023-10-02 | Biller Jonathan EVP and Chief Legal Officer | Sale 10b5-1 | −610 | $346.76 | $212K | 10,569 |
| 2023-09-29 | Biller Jonathan EVP and Chief Legal Officer | Shares withheld for taxes 10b5-1 | −408 | $350.72 | $143K | 11,179 |
| 2023-09-19 | Bozic Carmen EVP and CMO | Sale 10b5-1 | −5,651 | $351.00 | $2.0M | 51,905 |
| 2023-09-05 | Bozic Carmen EVP and CMO | Sale 10b5-1 | −5,651 | $352.66 | $2.0M | 57,556 |
| 2023-08-23 | Tatsis Ourania EVP, Chief Reg. & Quality Off. | Sale 10b5-1 | −2,500 | $355.00 | $888K | 48,637 |
| 2023-08-10 | Kearney Terrence C Director | Exercise or conversion 10b5-1 | +10,000 | $127.54 | $1.3M | 16,536 |
| 2023-08-10 | Kearney Terrence C Director | Sale 10b5-1 | −10,000 | $350.00 | $3.5M | 6,536 |
| 2023-08-10 | Kearney Terrence C Director | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −10,000 | 10,000 | ||
| 2023-08-10 | Tatsis Ourania EVP, Chief Reg. & Quality Off. | Sale 10b5-1 | −5,750 | $345.79 | $2.0M | 51,137 |
| 2023-08-10 | Sachdev Amit EVP, Chief Patient Officer | Sale 10b5-1 | −10,031 | $350.00 | $3.5M | 58,814 |
| 2023-08-09 | ALTSHULER DAVID EVP, Global Research and CSO | Sale 10b5-1 | −63 | $345.51 | $22K | 32,038 |
| 2023-08-09 | Bhatia Sangeeta N. Director | Sale 10b5-1 | −242 | $345.51 | $84K | 4,386 |
| 2023-07-17 | SACHS BRUCE I Director | Exercise or conversion 10b5-1 | +11,250 | $127.54 | $1.4M | 51,250 |
| 2023-07-17 | SACHS BRUCE I Director | Sale 10b5-1 | −1,697 | $355.54 | $603K | 49,553 |
| 2023-07-17 | SACHS BRUCE I Director | Sale 10b5-1 | −5,711 | $356.75 | $2.0M | 43,842 |
| 2023-07-17 | SACHS BRUCE I Director | Sale 10b5-1 | −3,842 | $357.29 | $1.4M | 40,000 |
| 2023-07-17 | SACHS BRUCE I Director | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −11,250 | 11,250 | ||
| 2023-07-17 | Kewalramani Reshma CEO & President | Sale 10b5-1 | −7,828 | $355.00 | $2.8M | 118,906 |
| 2023-07-14 | SACHS BRUCE I Director | Grant or award · Deferred Stock Units 10b5-1 | +124.72 | $350.79 | $44K | 14,524.97 |
Page 28 of 40 · 781 trades